Denali Therapeutics Inc
DNLIHealthcare·Biotechnology·USA·Mid·NASD·Nov 12 • 3:59 PM ET
18.89-0.84 (-4.26%)
2026-11-13 13:18 CET
Market cap
$3.03B
Revenue, TTM
21.38 USD m
Net income, TTM
-314.42 USD m
Free cash flow, TTM
-449.99 USD m
EPS diluted, TTM
-1.74
Price
DNLI against its 20, 50 and 200-day averagesPatternshover a marker to name it
30.8% under the 52-week high of 27.30 on 9 Jul 2026. 52-week low 15.34 on 5 Jan 2026. Last 15 sessions, 23.2% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 15
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
DNLI52-week range, 30% of the way up
15.3427.30
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 503 |
| IPO | Dec 08, 2017 |
| Beta | 1.08 |
| ATR, 14d | 0.91 |
| Rel volume | 0.00 |
| Short float | 9.79% |
| Insider own | 6.34% |
| Inst own | 95.87% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $3.03B |
| Enterprise Value | 2.55B |
| Income | -314.42M |
| Sales | 21.38M |
| Book / share | 5.78 |
| Cash / share | 3.22 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 503 |
| IPO | Dec 08, 2017 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 141.62 |
| Price / book | 3.27 |
| Price / cash | 5.87 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 119.13 |
| Quick Ratio | 5.94 |
| Current Ratio | 6.21 |
| Debt / equity | 0.04 |
| Long-term debt / equity | 0.03 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.74 |
|---|---|
| Earnings next year | -2.26 |
| Earnings next quarter | -0.61 |
| Earnings this year | 40.96% |
| Earnings next year | -28.78% |
| Earnings growth, 5 years | 16.88% |
| Past earnings growth | -4.56% - |
| Past sales growth | - - |
| Earnings vs last year | 40.59% |
| Sales vs last year | - |
| Earnings vs last quarter | 149.61% |
| Sales vs last quarter | - |
| Earnings | Nov 03 AMC |
| Surprise | 236.58% 40.28% |
Ownership
| Insiders own | 6.34% |
|---|---|
| Insider trades | -0.18% |
| Institutions own | 95.87% |
| Institution trades | 1.50% |
| Return on assets | -27.20% |
| Return on equity | -33.94% |
| Return on capital | -33.06% |
| Gross Margin | 21.42% |
| Operating margin | -2488.14% |
| Profit Margin | -1470.50% |
| 20-day average | -1.52% |
| 50-day average | -4.86% |
| 200-day average | -11.07% |
Technical
| Shares out | 160.26M |
|---|---|
| Shares floating | 150.12M |
| Short / float | 9.79% |
| Short ratio | 9.10 |
| Short interest | 14.69M |
| 52-week high | 27.30 -30.8% |
| 52-week low | 15.34 +23.1% |
| Volatility | 3.86% 4.54% |
| Average range | 0.91 |
| Strength index | 44.57 |
| Market sensitivity | 1.08 |
| Relative volume | 0.00 |
| Avg Volume | 1.62M |
| Volume | 0 |
Performance
| Perf Week | -4.21% |
|---|---|
| Perf Month | 5.71% |
| Perf Quarter | -22.58% |
| Perf Half Y | -2.58% |
| Perf YTD | 14.42% |
| Perf Year | 7.82% |
| Perf 3Y | 16.46% |
| Perf 5Y | -62.81% |
| Perf 10Y | - |
| Recommendation | 1.15 |
| Target Price | 36.19 |
| Prev Close | 18.89 |
| Price | 18.89 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Today | Initiated | Wells Fargo | Overweight | $35 | +85.3% |
| Jul 13, 2026 | Resumed | JP Morgan | Overweight | $29 | +53.5% |
| Mar 26, 2026 | Reiterated | H.C. Wainwright | Buy | $32 → $42 | +122.3% |
| Feb 24, 2026 | Initiated | Wolfe Research | Peer Perform | ||
| Jan 07, 2026 | Resumed | UBS | Buy | $25 | +32.3% |
| Apr 10, 2025 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | ||
| Mar 07, 2025 | Resumed | Morgan Stanley | Overweight | $41 → $33 | +74.7% |
| Feb 11, 2025 | Initiated | Deutsche Bank | Buy | $31 | +64.1% |
| Jan 07, 2025 | Initiated | Robert W. Baird | Outperform | $31 | +64.1% |
| Jan 03, 2025 | Initiated | William Blair | Outperform |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| RGNX | Regenxbio Inc | 538.23M |
| RARE | Ultragenyx Pharmaceutical Inc | 1.65B |
| ALEC | Alector Inc | 381.13M |
| VYGR | Voyager Therapeutics Inc | 106.41M |
| ARVN | Arvinas Inc | 438.44M |
| ACAD | Acadia Pharmaceuticals Inc | 3.13B |
| BMRN | Biomarin Pharmaceutical Inc | 10.95B |
| TAK | Takeda Pharmaceutical Co ADR | 68.79B |
| BIIB | Biogen Inc | 37.04B |
| PRTA | Prothena Corp Plc | 421.05M |
Insider trading
latest 14 of 17| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Chin Peter Scott | Chief Medical Officer | Sep 04 '26 | Sale | 22.29 | 1,654 | 36,868 | 204,538 | Sep 09 04:44 PM |
| Chin Peter Scott | Officer | Sep 04 '26 | Proposed Sale | 22.29 | 1,654 | 36,867 | Sep 04 08:38 PM | |
| Thornberry Nancy | Director | Sep 02 '26 | Sale | 22.90 | 11,439 | 261,929 | 19,686 | Sep 04 05:02 PM |
| Schuth Alexander O. | COFO and Secretary | Sep 01 '26 | Sale | 23.44 | 2,768 | 64,882 | 278,995 | Sep 03 04:17 PM |
| NANCY THORNBERRY | Director | Sep 02 '26 | Proposed Sale | 23.27 | 11,439 | 266,128 | Sep 02 04:31 PM | |
| ALEXANDER SCHUTH | Officer | Sep 01 '26 | Proposed Sale | 23.76 | 2,768 | 65,768 | Sep 01 04:47 PM | |
| Schuth Alexander O. | COFO and Secretary | Aug 11 '26 | Sale | 25.07 | 2,857 | 71,625 | 281,763 | Aug 13 05:01 PM |
| Schuth Alexander O. | Officer | Aug 11 '26 | Proposed Sale | 25.07 | 2,857 | 71,624 | Aug 11 05:39 PM | |
| CAROLE HO | Former Affiliate | Feb 05 '26 | Proposed Sale | 20.29 | 39,490 | 801,394 | Feb 05 04:14 PM | |
| CAROLE HO | Former Affiliate | Feb 04 '26 | Proposed Sale | 21.18 | 150,000 | 3,176,970 | Feb 04 04:16 PM | |
| CAROLE HO | Former Affiliate | Feb 03 '26 | Proposed Sale | 22.16 | 150,000 | 3,324,060 | Feb 03 04:47 PM | |
| Watts Ryan J. | President and CEO | Jan 06 '26 | Sale | 16.50 | 35,198 | 580,767 | 296,833 | Jan 08 04:20 PM |
| Schuth Alexander O. | COFO and Secretary | Jan 06 '26 | Sale | 16.50 | 17,218 | 284,097 | 282,828 | Jan 08 04:19 PM |
| Ho Carole | Consultant | Jan 06 '26 | Proposed Sale | 16.50 | 17,218 | 284,097 | Jan 06 08:28 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 80.23B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| VBK | Vanguard Morningstar Small-Cap Growth ETF | AUM: 22.68B |
| TCAF | T. Rowe Price Capital Appreciation Equity ETF | AUM: 8.35B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
News
latest 14 of 200- Guggenheim reaffirms top pick in Biotech after Q3 results (Investing.com)
- Denali's AVLAYAH Launch Blows Past Guidance As Q4 Outlook Nearly Triples, But A Shrinking Stock Prices In Doubt (Earnings Whispers) +7.76%
- Denali Therapeutics soars on earnings beat (Investing.com)
- Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH (tividenofusp alfa-eknm) as Best Biotechnology Product (GlobeNewswire)
- Denali Faces A Revenue Test As Shares Slide Toward Post-Earnings Lows (Earnings Whispers)
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026 (GlobeNewswire)
- Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
- Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 (GlobeNewswire)
- Beyond weight loss: Lilly aims for leadership in brain science (Pharma Voice)
- VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform (Exec Edge)
- Slate Medicines Appoints Mark W. Hahn to Board of Directors (Exec Edge)
- Acumen Pharmaceuticals Shows Early Alzheimers Disease Insights (Exec Edge)
- Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
Quarterly earnings
2026Q3 EPS 0.370 beat -0.271, from -0.740 a year earlier. Sales 17.78 beat 12.67, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-03 16:30 | 0.370 | -0.271 | 0.370 | 17.78 | 12.67 | EPS -236.6% · sales +40.3% | vs 2025Q3, year-ago quarter · EPS -150.0% · sales - | 20 EPS · 17 sales | Open +9.15% vs SPY +1.15%. Close +7.76% vs SPY +1.65% |
| 2026Q2ended 2026-06-30 | 2026-08-06 16:30 | -0.680 | -0.513 | -0.681 | 3.60 | 2.15 | EPS +32.6% · sales +67.3% | vs 2025Q2, year-ago quarter · EPS -5.6% · sales - | 16 EPS · 14 sales | Open +2.75% vs SPY +0.32%. Close +0.40% vs SPY +0.61% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -0.690 | -0.723 | -0.688 | 0.00 | 2.57 | EPS -4.6% · sales -100.0% | vs 2025Q1, year-ago quarter · EPS -11.5% · sales - | 18 EPS · 13 sales | Open -1.37% vs SPY +0.46%. Close -0.46% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-02-26 16:30 | -0.730 | -0.737 | -0.733 | 0.00 | 3.08 | EPS -0.9% · sales -100.0% | vs 2024Q4, year-ago quarter · EPS +9.0% · sales - | 18 EPS · 13 sales | Open -1.31% vs SPY -0.90%. Close -1.12% vs SPY -0.48% |
| 2025Q3ended 2025-09-30 | 2025-11-06 16:30 | -0.740 | -0.748 | -0.736 | 0.00 | 1.36 | EPS -1.0% · sales -100.0% | vs 2024Q3, year-ago quarter · EPS +17.5% · sales - | 17 EPS · 11 sales | Open +1.01% vs SPY -0.36%. Close +4.23% vs SPY +0.10% |
| 2025Q2ended 2025-06-30 | 2025-08-11 16:30 | -0.720 | -0.710 | -0.724 | 0.00 | 7.05 | EPS +1.4% · sales -100.0% | vs 2024Q2, year-ago quarter · EPS +22.0% · sales - | 17 EPS · 12 sales | Open +0.72% vs SPY +0.37%. Close -5.03% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-06 16:30 | -0.780 | -0.697 | -0.777 | 0.00 | 1.36 | EPS +12.0% · sales -100.0% | vs 2024Q1, year-ago quarter · EPS +14.7% · sales - | 16 EPS · 10 sales | Open -0.14% vs SPY +0.24%. Close +2.51% vs SPY +0.42% |
| 2024Q4ended 2024-12-31 | 2025-02-27 16:30 | -0.670 | -0.799 | -0.675 | 0.00 | 9.21 | EPS -16.1% · sales -100.0% | vs 2023Q4, year-ago quarter · EPS -22.1% · sales - | 18 EPS · 14 sales | Open +1.24% vs SPY +0.09%. Close -10.97% vs SPY +1.56% |
| 2024Q3ended 2024-09-30 | 2024-11-06 16:30 | -0.630 | -0.595 | -0.633 | 0.00 | 6.30 | EPS +5.9% · sales -100.0% | vs 2023Q3, year-ago quarter · EPS -12.5% · sales -100.0% | 15 | Open -1.02% vs SPY +0.35%. Close +0.17% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-01 08:30 | -0.590 | -0.703 | -0.587 | 0.00 | 10.00 | EPS -16.0% · sales -100.0% | vs 2023Q2, year-ago quarter · EPS -145.4% · sales -100.0% | 15 EPS · 14 sales | Open -2.34% vs SPY +0.32%. Close -4.27% vs SPY -1.42% |
| 2024Q1ended 2024-03-31 | 2024-05-07 16:30 | -0.680 | -0.695 | -0.681 | 0.00 | 14.02 | EPS -2.1% · sales -100.0% | vs 2023Q1, year-ago quarter · EPS -15.0% · sales -100.0% | 16 EPS · 13 sales | Open +0.89% vs SPY -0.36%. Close +12.17% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-02-27 08:30 | -0.860 | -0.804 | -0.864 | 0.00 | 7.98 | EPS +7.0% · sales -100.0% | vs 2022Q4, year-ago quarter · EPS +14.7% · sales -100.0% | 15 EPS · 14 sales | Open +18.06% vs SPY +0.14%. Close +38.25% vs SPY +0.19% |
| 2023Q3ended 2023-09-30 | 2023-11-07 16:30 | -0.720 | -0.810 | -0.722 | 1.27 | 11.16 | EPS -11.1% · sales -88.6% | vs 2022Q3, year-ago quarter · EPS -14.3% · sales -64.4% | 15 EPS · 13 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-08 16:30 | 1.300 | -0.694 | 1.301 | 294.12 | 39.51 | EPS -287.2% · sales +644.5% | vs 2022Q2, year-ago quarter · EPS -370.8% · sales +460.4% | 14 EPS · 11 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-08 16:30 | -0.800 | -0.701 | -0.804 | 35.14 | 28.72 | EPS +14.2% · sales +22.3% | vs 2022Q1, year-ago quarter · EPS +50.9% · sales -16.6% | 15 EPS · 13 sales | - |
| 2022Q4ended 2022-12-31 | 2023-02-27 16:30 | -0.750 | -0.788 | -0.743 | 10.28 | 13.12 | EPS -4.8% · sales -21.6% | vs 2021Q4, year-ago quarter · EPS +21.0% · sales -17.8% | 16 EPS · 13 sales | - |
Annual earnings
2025FY EPS -2.970 missed -2.954, from -2.570 a year earlier. Sales 0.00 missed 2.50, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.319 | - | - | 678.49 | - |
| 2029FYestimate | - | -1.242 | - | - | 436.15 | - |
| 2028FYestimate | - | -1.705 | - | - | 319.22 | - |
| 2027FYestimate | - | -2.258 | - | - | 163.52 | - |
| 2026FYestimate | - | -1.753 | - | - | 52.65 | - |
| 2025FY | -2.970 | -2.954 | -2.970 | 0.00 | 2.50 | - |
| 2024FY | -2.570 | -2.778 | -2.571 | 0.00 | 11.71 | - |
| 2023FY | -1.060 | -0.995 | -1.057 | 330.53 | 337.7 | - |
| 2022FY | -2.600 | -2.633 | -2.597 | 108.46 | 109.51 | - |
| 2021FY | -2.390 | -2.265 | -2.391 | 48.66 | 75.99 | - |
| 2020FY | 0.630 | -1.539 | 0.631 | 335.66 | 92.10 | 132.95 |
| 2019FY | -2.070 | -2.081 | -2.067 | 26.68 | 31.81 | - |
| 2018FY | -0.390 | -1.337 | -0.391 | 129.11 | 30.35 | - |
| 2017FY | -5.890 | -1.746 | -5.890 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 17.78, from 0.00 a year earlier. Operating margin -712.88%
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.75 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-04 | -1.75 | -20.0% |
| 2026Q4 | E | per share | 2026-11-04 | -0.61 | -3.9% |
| 2026FY | R | per share | 2026-11-04 | -1.75 | -20.0% |
| 2026Q4 | R | per share | 2026-11-04 | -0.61 | -3.9% |
| 2026FY | S | per share | 2026-11-04 | 52.65 | +30.5% |
| 2026Q4 | S | per share | 2026-11-04 | 31.75 | +39.3% |
| 2026Q3 | S | per share | 2026-10-24 | 12.22 | 0.0% |
| 2026Q3 | E | per share | 2026-10-21 | -0.32 | 0.0% |
| 2026Q3 | R | per share | 2026-10-21 | -0.32 | 0.0% |
| 2026Q2 | E | per share | 2026-08-05 | -0.51 | 0.0% |
| 2026Q2 | R | per share | 2026-08-05 | -0.51 | 0.0% |
| 2026Q2 | S | per share | 2026-07-29 | 2.15 | +0.0% |
| 2026Q1 | S | per share | 2026-05-02 | 2.57 | 0.0% |
| 2026Q1 | E | per share | 2026-04-20 | -0.72 | 0.0% |
| 2026Q1 | R | per share | 2026-04-20 | -0.72 | 0.0% |
| 2025Q4 | E | per share | 2026-02-23 | -0.74 | 0.0% |
| 2025Q4 | R | per share | 2026-02-23 | -0.74 | 0.0% |
| 2025FY | E | per share | 2026-02-20 | -2.95 | -0.1% |
| 2025FY | R | per share | 2026-02-20 | -2.95 | -0.1% |
| 2025FY | S | per share | 2026-02-20 | 2.50 | -6.3% |
| 2025Q4 | S | per share | 2026-02-20 | 3.08 | -7.7% |
| 2025Q3 | E | per share | 2025-11-01 | -0.75 | 0.0% |
| 2025Q3 | R | per share | 2025-11-01 | -0.75 | 0.0% |
| 2025Q3 | S | per share | 2025-10-31 | 1.36 | -9.1% |
| 2025Q2 | E | per share | 2025-08-06 | -0.71 | +0.0% |
| 2025Q2 | R | per share | 2025-08-06 | -0.71 | +0.0% |
| 2025Q2 | S | per share | 2025-07-21 | 7.05 | 0.0% |
| 2025Q1 | E | per share | 2025-04-22 | -0.70 | -0.2% |
| 2025Q1 | R | per share | 2025-04-22 | -0.70 | -0.2% |
| 2025Q1 | S | per share | 2025-04-22 | 1.36 | -10.0% |
| 2024Q4 | E | per share | 2025-02-12 | -0.80 | +0.2% |
| 2024Q4 | R | per share | 2025-02-12 | -0.80 | +0.2% |
| 2024FY | E | per share | 2025-02-10 | -2.78 | 0.0% |
| 2024FY | R | per share | 2025-02-10 | -2.78 | 0.0% |
| 2024FY | S | per share | 2025-02-10 | 11.71 | +0.0% |
| 2024Q4 | S | per share | 2025-01-26 | 9.21 | 0.0% |
| 2024Q3 | E | per share | 2024-10-19 | -0.60 | 0.0% |
| 2024Q3 | R | per share | 2024-10-19 | -0.60 | 0.0% |
| 2024Q3 | S | per share | 2024-10-19 | 6.30 | 0.0% |
| 2024Q2 | E | per share | 2024-07-31 | -0.69 | +0.0% |
| 2024Q2 | R | per share | 2024-07-31 | -0.69 | +0.0% |
| 2024Q2 | S | per share | 2024-07-24 | 10.00 | 0.0% |
| 2024Q1 | E | per share | 2024-04-30 | -0.69 | -0.2% |
| 2024Q1 | R | per share | 2024-04-30 | -0.69 | -0.2% |
| 2024Q1 | S | per share | 2024-04-08 | 14.02 | -0.9% |
| 2023FY | S | - | 2024-02-20 | 337.7 | 0.0% |
| 2023FY | E | per share | 2024-02-15 | -1.00 | -3.9% |
| 2023FY | R | per share | 2024-02-15 | -1.00 | -3.9% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -5.89 | -0.391 | -2.067 | 0.631 | -2.391 | -2.597 | -1.057 | -2.571 | -2.969 | -1.7367 | - |
| Sales USD millions | 0 | 129 | 27 | 336 | 49 | 108 | 331 | 0 | 0 | 21 | - |
| Shares million shares | 87 | 95 | 96 | 121 | 122 | 136 | 138 | 143 | 156 | - | 160 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.633 | -0.675 | -0.777 | -0.724 | -0.736 | -0.733 | -0.688 | -0.681 | 0.365 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 18 |
| Shares million shares | 144 | 143 | 145 | 146 | 147 | 156 | 159 | 160 | 160 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.38 | 0.00 | 0.00-100.0% | 330.53+204.7% | 108.46+122.9% | 48.66-85.5% | 335.66+1158.1% | 26.68-79.3% | 129.16 |
| Cost of Goods Sold Incl. D&A | 16.80 | 14.81+90.1% | 7.79-53.4% | 16.73+138.0% | 7.03+25.3% | 5.61 | - | - | 7.42 |
| Gross Profit | 4.58 | -14.81 | -7.79-102.5% | 313.81+209.4% | 101.43+135.6% | 43.05 | - | - | 121.75 |
| Selling, General and Administrative Excl. Other | 536.59 | 540.53+9.4% | 494.08-3.2% | 510.50+15.5% | 442.18+30.5% | 338.80+27.0% | 266.77+15.8% | 230.37+43.8% | 160.22 |
| Research and Development | 404.87 | 418.78+5.6% | 396.44-6.5% | 423.88+18.2% | 358.73+35.2% | 265.35+24.8% | 212.62+10.8% | 191.88+41.8% | 135.28 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -532.01 | -555.34 | -501.88 | -196.70 | -340.74 | -295.75-571.5% | 62.72 | -211.68 | -38.47 |
| Interest Expense | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.10-107.7% | 1.30-84.0% | 8.10 |
| Net Income Before Taxes | -314.32 | -512.44 | -422.70 | -145.19 | -325.97 | -291.16-504.6% | 71.96 | -197.97 | -36.24 |
| Income Taxes | 0.10 | 0.10+42.9% | 0.07+133.3% | 0.03+50.0% | 0.02 | -0.57-169.5% | 0.82 | -0.35 | 0.00 |
| Consolidated Net Income | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58-508.5% | 71.14 | -197.61 | -36.24 |
| Net Income From Continuing Operations | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58-508.5% | 71.14 | -197.61 | -36.24 |
| Net Income | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58-508.5% | 71.14 | -197.61 | -36.24 |
| EPS (Recurring) per share | -1.64 | -2.97 | -2.57 | -1.06 | -2.60 | -2.39-479.4% | 0.63 | -2.06 | -0.33 |
| EPS (Basic, Before Extraordinaries) per share | -1.73 | -2.97 | -2.57 | -1.06 | -2.60 | -2.39-467.7% | 0.65 | -2.07 | -0.39 |
| EPS (Diluted) per share | -1.74 | -2.97 | -2.57 | -1.06 | -2.60 | -2.39-479.4% | 0.63 | -2.07 | -0.39 |
| EBITDA | -515.50 | -540.53 | -494.08 | -179.97 | -333.71 | -290.14-521.2% | 68.89 | -203.69 | -31.06 |
| Non-Operating Income (Expense) | 217.69 | 42.90-45.8% | 79.17+53.7% | 51.51+248.7% | 14.77+221.8% | 4.59-49.8% | 9.14-39.1% | 15.02+45.4% | 10.33 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 92.81 | 99.63+22.6% | 81.27-4.8% | 85.40+8.3% | 78.88+26.8% | 62.23+69.3% | 36.76+31.2% | 28.02+49.1% | 18.79 |
| Price To Earnings Ratio ratio statement ratio, not the snapshot | - | - | - | - | - | - | 329.37 | - | - |
| Price To Sales Ratio ratio | 185.68 | - | - | 8.92 | 32.19 | 111.38 | 28.12 | 62.43 | 14.82 |
| Gross Margin % | 21.42 | - | - | 94.94 | 93.52 | 88.47 | - | - | 94.26 |
| Operating Margin % | -2,488.14 | - | - | -59.51 | -314.16 | -607.78 | 18.69 | -793.48 | -29.79 |
| Net Margin % | -1,470.50 | - | - | -43.94 | -300.56 | -597.15 | 21.19 | -740.74 | -28.06 |
| Shares Outstanding million shares | 160.26 | 156.18+9.5% | 142.63+3.1% | 138.39+1.8% | 135.97+11.2% | 122.28+1.5% | 120.53+25.3% | 96.19+1.6% | 94.66 |
| Market Capitalization | 3,027.90 | 3,027.90+3.2% | 2,933.13-1.1% | 2,965.71-21.5% | 3,776.99-30.7% | 5,446.82-45.8% | 10,044.33+500.4% | 1,672.86-14.7% | 1,961.81 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 17.78 | 3.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 4.68+58.6% | 5.49+80.6% | 2.85+22.3% | 3.78+104.3% | 2.95+60.3% | 3.04+56.7% | 2.33+7.9% | 1.85-15.1% |
| Gross Profit | 13.10 | -1.89 | -2.85 | -3.78 | -2.95 | -3.04 | -2.33 | -1.85 |
| Selling, General and Administrative Excl. Other | 139.85+4.0% | 128.65-2.5% | 134.51-6.1% | 133.58+4.4% | 134.49+10.8% | 131.92+15.1% | 143.25+10.1% | 127.99-1.8% |
| Research and Development | 106.10+4.1% | 97.02-5.5% | 103.85-10.7% | 97.91-1.9% | 101.95+3.8% | 102.70+12.4% | 116.23+8.6% | 99.79-7.4% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -126.75 | -130.54 | -137.36 | -137.37 | -137.43 | -134.96 | -145.58 | -129.85 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | 70.13 | -127.55 | -128.45 | -128.45 | -126.90 | -124.12 | -132.97 | -114.69 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.10+42.9% | 0.00 | 0.00 | 0.00 | 0.07+133.3% |
| Consolidated Net Income | 70.13 | -127.55 | -128.45 | -128.55 | -126.90 | -124.12 | -132.97 | -114.75 |
| Net Income From Continuing Operations | 70.13 | -127.55 | -128.45 | -128.55 | -126.90 | -124.12 | -132.97 | -114.75 |
| Net Income | 70.13 | -127.55 | -128.45 | -128.55 | -126.90 | -124.12 | -132.97 | -114.75 |
| EPS (Recurring) per share | 0.37 | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
| EPS (Basic, Before Extraordinaries) per share | 0.37 | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
| EPS (Diluted) per share | 0.37 | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
| EBITDA | -122.26 | -125.14 | -134.51 | -133.58 | -134.49 | -131.92 | -143.25 | -127.99 |
| Non-Operating Income (Expense) | 196.88+1769.7% | 2.99-72.4% | 8.91-29.3% | 8.92-41.2% | 10.53-34.1% | 10.84-38.3% | 12.61-58.6% | 15.16+15.5% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 22.86-9.1% | 22.91-9.8% | 23.09-8.2% | 23.95+20.9% | 25.14+1.1% | 25.39+1.2% | 25.16-9.6% | 19.81-3.5% |
| Price To Sales Ratio ratio | 185.68 | 1,336.77 | - | - | - | - | - | - |
| Gross Margin % | 73.66 | -52.39 | - | - | - | - | - | - |
| Operating Margin % | -712.97 | -3,622.11 | - | - | - | - | - | - |
| Net Margin % | 394.45 | -3,539.21 | - | - | - | - | - | - |
| Shares Outstanding million shares | 160.26+9.3% | 159.76+9.7% | 158.66+9.2% | 156.18+9.5% | 146.63+1.9% | 145.69+1.8% | 145.25+1.9% | 142.63+3.1% |
| Market Capitalization | 3,027.90+42.6% | 4,082.02+100.8% | 3,044.95+54.2% | 2,578.17-12.1% | 2,123.00-49.1% | 2,032.41-38.6% | 1,974.20-30.9% | 2,933.13-1.1% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 867.88+4.3% | 832.33-19.5% | 1,034.51-22.6% | 1,336.21+54.4% | 865.41-41.1% | 1,469.70+253.8% | 415.36-10.5% | 464.30+14.3% | 406.23 |
| Short Term Receivables | 2.18+45.3% | 1.50-44.4% | 2.70-46.0% | 5.00-66.5% | 14.93 | 0.00 | 0.00-100.0% | 8.55+1758.7% | 0.46 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 30.600.0% | 30.61+13.7% | 26.93-13.4% | 31.10+84.0% | 16.90-34.9% | 25.96+76.8% | 14.68+83.7% | 7.99+173.6% | 2.92 |
| Total Current Assets | 900.66+4.2% | 864.44-18.8% | 1,064.14-22.5% | 1,372.32+53.0% | 897.23-40.0% | 1,495.65+247.8% | 430.03-10.6% | 480.84+17.4% | 409.61 |
| Net Property, Plant & Equipment | 119.94-4.5% | 125.63+75.4% | 71.64-3.9% | 74.52+7.1% | 69.61-5.2% | 73.46-8.9% | 80.66+220.6% | 25.16+68.6% | 14.92 |
| Total Investments and Advances | 101.42-71.9% | 360.97+22460.6% | 1.60+6.7% | 1.50-99.6% | 426.95+1148.4% | 34.20-17.4% | 41.39-72.3% | 149.38+142.1% | 61.70 |
| Other Assets | 22.84-1.3% | 23.14+39.9% | 16.54+39.0% | 11.90+14.8% | 10.37+980.2% | 0.96-17.2% | 1.16-82.5% | 6.61+1249.0% | 0.49 |
| Total Assets | 1,144.85-16.7% | 1,374.18+19.1% | 1,153.92-21.0% | 1,460.24+4.0% | 1,404.16-12.5% | 1,604.28+190.0% | 553.23-16.4% | 661.98+36.0% | 486.72 |
| Short Term Debt Incl. Current Port. of LT Debt | 9.55-20.6% | 12.03+65.7% | 7.26-0.8% | 7.32+34.3% | 5.45+16.2% | 4.69+27.8% | 3.67 | 0.00 | 0.00 |
| Accounts Payable | 3.33-70.1% | 11.14+17.5% | 9.48+239.8% | 2.79-41.6% | 4.78+346.7% | 1.07-58.7% | 2.59+37.0% | 1.89-30.5% | 2.72 |
| Other Current Liabilities | 85.47+8.1% | 79.04+29.1% | 61.24-82.7% | 353.81-3.9% | 368.01+458.1% | 65.94+68.7% | 39.09+26.5% | 30.89+169.8% | 11.45 |
| Total Current Liabilities | 98.35-3.8% | 102.21+31.1% | 77.98-78.6% | 363.92-3.8% | 378.25+427.5% | 71.70+58.1% | 45.34+38.3% | 32.79+131.6% | 14.16 |
| Long Term Debt | 32.74-22.6% | 42.29-6.0% | 44.98-15.2% | 53.03-9.4% | 58.55-8.8% | 64.17-6.8% | 68.86 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00-100.0% | 0.86-83.0% | 5.07-98.4% | 317.88+620.3% | 44.13-46.4% | 82.35+1118.2% | 6.76 |
| Total Liabilities | 131.09-9.3% | 144.50+17.5% | 122.96-70.6% | 417.81-5.4% | 441.87-2.6% | 453.75+186.6% | 158.34+37.5% | 115.14+450.1% | 20.93 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 1,013.76-17.6% | 1,229.68+19.3% | 1,030.95-1.1% | 1,042.43+8.3% | 962.29-16.4% | 1,150.53+191.4% | 394.89-27.8% | 546.85+17.4% | 465.80 |
| Total Shareholders Equity | 1,013.76-17.6% | 1,229.68+19.3% | 1,030.95-1.1% | 1,042.43+8.3% | 962.29-16.4% | 1,150.53+191.4% | 394.89-27.8% | 546.85+17.4% | 465.80 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,013.76-17.6% | 1,229.68+19.3% | 1,030.95-1.1% | 1,042.43+8.3% | 962.29-16.4% | 1,150.53+191.4% | 394.89-27.8% | 546.85+17.4% | 465.80 |
| Total Liabilities & Stockholders Equity | 1,144.85-16.7% | 1,374.18+19.1% | 1,153.92-21.0% | 1,460.24+4.0% | 1,404.16-12.5% | 1,604.28+190.0% | 553.23-16.4% | 661.98+36.0% | 486.72 |
| Book Value Per Share per share | 6.49-24.7% | 8.62+15.7% | 7.45-2.9% | 7.67-2.5% | 7.87-17.6% | 9.55+132.4% | 4.11-28.9% | 5.78+8.6% | 5.32 |
| Tangible Book Value Per Share per share | 6.49-24.7% | 8.62+15.7% | 7.45-2.9% | 7.67-2.5% | 7.87-17.6% | 9.55+132.4% | 4.11-28.9% | 5.78+8.6% | 5.32 |
| Full-Time Employees people | 503+19.2% | 422-5.2% | 445+4.2% | 427+12.4% | 380+30.6% | 291+11.5% | 261+45.8% | 179+37.7% | 130 |
| Price to Book Ratio ratio | 3.27 | 2.22 | 2.65 | 4.24 | 5.67 | 8.77 | 4.24 | 3.58 | -9.06 |
| Return on Assets % | -40.69 | -33.45 | -11.11 | -22.76 | -19.32 | 6.59 | -32.52 | -6.31 | -23.27 |
| Return on Equity % | -45.69 | -37.40 | -14.01 | -32.52 | -27.51 | 9.21 | -41.97 | -7.16 | -24.49 |
| Return on Invested Capital % | -48.98 | -33.24 | -13.50 | -29.76 | -28.46 | 5.86 | -42.61 | -6.63 | -18.93 |
| Quick Ratio ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 |
| Current Ratio ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58-508.5% | 71.14 | -197.61 | -36.24 |
| Depreciation | 19.23 | 14.81+90.1% | 7.79-53.4% | 16.73+138.0% | 7.03+25.3% | 5.61-9.1% | 6.17-22.8% | 7.99+7.7% | 7.42 |
| Other Funds (Non Cash) | -103.48 | 84.98+68.8% | 50.35-16.7% | 60.43-38.5% | 98.27+4.5% | 94.00+86.4% | 50.44+48.9% | 33.87+111.0% | 16.05 |
| Funds from Operations | -398.68 | -412.75 | -364.63 | -68.06 | -220.69 | -190.98-249.5% | 127.75 | -155.75 | -12.78 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -45.51 | 0.15-99.1% | 16.94 | -289.93 | -24.03 | -20.41-107.1% | 288.40+6816.1% | 4.17-93.4% | 62.89 |
| Cash from Operating Activities | -444.19 | -412.60 | -347.69 | -357.99 | -244.72 | -211.39-150.8% | 416.15 | -151.58-402.4% | 50.12 |
| Capital Expenditures | -41.80 | -9.50 | -15.91 | -12.94 | -17.83 | -8.50 | -3.10 | -17.92 | -3.39 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 194.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -124.85 | 264.78 | -72.84-127.8% | 262.25 | -123.55 | -13.13 | -620.11-474.4% | 165.63 | -284.03 |
| Purchase of Investments | -1,002.51 | -441.26 | -1,229.96 | -1,813.70 | -1,115.04 | -1,422.94 | -1,285.47 | -369.70 | -557.93 |
| Sale Or Maturity of Investments | 877.65 | 706.05-39.0% | 1,157.12-44.3% | 2,075.95+109.4% | 991.49-29.7% | 1,409.81+111.9% | 665.36+24.3% | 535.33+95.4% | 273.90 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 27.34 | 255.28 | -88.76-135.6% | 249.31 | -141.39 | -21.63 | -623.21-521.9% | 147.71 | -287.42 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 228.83 | 197.38-61.8% | 516.64+2799.2% | 17.82-94.3% | 310.67+1505.5% | 19.35-97.0% | 634.75+10154.4% | 6.19-93.6% | 97.02 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 228.83 | 197.38-61.8% | 516.64+2799.2% | 17.82-94.3% | 310.67+1505.5% | 19.35-97.0% | 634.75+10154.4% | 6.19-93.6% | 97.02 |
| Proceedsfrom Stock Options | 201.29 | 188.93-62.2% | 499.25 | 0.00-100.0% | 296.21 | 0.00-100.0% | 614.09 | 0.00-100.0% | 93.02 |
| Issuance or Reduction of Debt, Net | -0.08 | -8.17 | -32.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -0.08 | -8.17 | -32.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.08 | -8.17 | -32.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 200.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 428.75 | 189.22-60.9% | 484.30+2617.7% | 17.82-94.3% | 310.67+1505.5% | 19.35-97.0% | 634.75+10154.4% | 6.19-93.6% | 97.02 |
| Net Change in Cash | 11.91 | 31.90-33.3% | 47.85 | -90.86 | -75.43 | -213.67-150.0% | 427.69+18255.8% | 2.33 | -140.29 |
| Free Cash Flow | -449.99 | -422.10 | -363.61 | -370.93 | -262.55 | -219.89-153.2% | 413.06 | -169.50-462.8% | 46.72 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | - | - | - | - | - | - | 22.85 | - | 40.96 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 516.20-39.1% | 710.47-21.0% | 987.68+20.8% | 867.88+4.3% | 848.20+1.4% | 898.95+0.3% | 817.93-12.7% | 832.33-19.5% |
| Short Term Receivables | 18.88+893.7% | 5.43+287.9% | 1.60-5.9% | 2.18+45.3% | 1.90+35.7% | 1.400.0% | 1.70-10.5% | 1.50-44.4% |
| Inventories | 26.27 | 4.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 30.36-6.6% | 33.89-1.3% | 33.47-43.3% | 30.600.0% | 32.49+5.2% | 34.35+11.0% | 59.01+69.5% | 30.61+13.7% |
| Total Current Assets | 591.71-33.0% | 753.93-19.3% | 1,022.75+16.4% | 900.66+4.2% | 882.60+1.6% | 934.71+0.7% | 878.64-9.8% | 864.44-18.8% |
| Net Property, Plant & Equipment | 109.30-11.3% | 113.42-12.8% | 117.27-9.7% | 119.94-4.5% | 123.21+8.8% | 130.10+79.2% | 129.93+80.0% | 125.63+75.4% |
| Total Investments and Advances | 509.48+1732.7% | 232.63+185.2% | 66.89-72.0% | 101.42-71.9% | 27.80-93.8% | 81.56-82.0% | 238.94-51.5% | 360.97+22460.6% |
| Intangible Assets | 34.50 | 35.25 | 36.00 | - | - | - | - | - |
| Other Assets | 11.05-49.8% | 22.73+14.4% | 23.12-3.0% | 22.84-1.3% | 22.01-11.6% | 19.87-59.4% | 23.83-44.6% | 23.14+39.9% |
| Total Assets | 1,256.04+19.0% | 1,157.95-0.7% | 1,266.02-0.4% | 1,144.85-16.7% | 1,055.62-27.4% | 1,166.24-22.4% | 1,271.34-19.6% | 1,374.18+19.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 10.51+14.7% | 10.18+14.8% | 9.86+14.8% | 9.55-20.6% | 9.16+13.9% | 8.87+14.2% | 8.59+14.4% | 12.03+65.7% |
| Accounts Payable | 13.70+103.0% | 11.81+8.9% | 40.38+377.3% | 3.33-70.1% | 6.75-29.6% | 10.84-22.2% | 8.46-28.7% | 11.14+17.5% |
| Other Current Liabilities | 71.05-4.3% | 68.09-4.6% | 59.92-19.9% | 85.47+8.1% | 74.24+6.9% | 71.34+35.0% | 74.83+18.4% | 79.04+29.1% |
| Total Current Liabilities | 95.26+5.7% | 90.08-1.1% | 110.16+19.9% | 98.35-3.8% | 90.15+3.5% | 91.06+22.2% | 91.88+11.3% | 102.21+31.1% |
| Long Term Debt | 24.73-29.8% | 27.50-27.0% | 30.19-24.6% | 32.74-22.6% | 35.24-20.8% | 37.69-8.0% | 40.05-6.9% | 42.29-6.0% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 209.66+5089.6% | 205.19+1865.4% | 199.58+1092.9% | 0.00 | 4.04+2.5% | 10.44 | 16.73 | 0.00 |
| Total Liabilities | 329.65+154.7% | 322.78+131.9% | 339.93+128.7% | 131.09-9.3% | 129.42-4.5% | 139.19+20.5% | 148.66+18.3% | 144.50+17.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 926.39+0.0% | 835.18-18.7% | 926.10-17.5% | 1,013.76-17.6% | 926.20-29.8% | 1,027.05-26.0% | 1,122.69-22.9% | 1,229.68+19.3% |
| Total Shareholders Equity | 926.39+0.0% | 835.18-18.7% | 926.10-17.5% | 1,013.76-17.6% | 926.20-29.8% | 1,027.05-26.0% | 1,122.69-22.9% | 1,229.68+19.3% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 926.39+0.0% | 835.18-18.7% | 926.10-17.5% | 1,013.76-17.6% | 926.20-29.8% | 1,027.05-26.0% | 1,122.69-22.9% | 1,229.68+19.3% |
| Total Liabilities & Stockholders Equity | 1,256.04+19.0% | 1,157.95-0.7% | 1,266.02-0.4% | 1,144.85-16.7% | 1,055.62-27.4% | 1,166.24-22.4% | 1,271.34-19.6% | 1,374.18+19.1% |
| Book Value Per Share per share | 5.78-8.5% | 5.23-25.8% | 5.84-24.5% | 6.49-24.7% | 6.32-31.1% | 7.05-27.2% | 7.73-24.3% | 8.62+15.7% |
| Tangible Book Value Per Share per share | 5.57-11.9% | 5.01-28.9% | 5.61-27.4% | 6.49-24.7% | 6.32-31.1% | 7.05-27.2% | 7.73-24.3% | 8.62+15.7% |
| Full-Time Employees people | - | - | 507 | 503+19.2% | 517 | 486 | - | 422-5.2% |
| Price to Book Ratio ratio | 3.27 | 4.41 | 2.96 | 2.61 | 2.06 | 1.81 | 1.58 | 2.22 |
| Return on Assets % | -27.20 | -44.01 | -40.04 | -40.69 | -39.75 | -35.90 | -31.83 | -33.45 |
| Return on Equity % | -33.94 | -54.93 | -49.59 | -45.69 | -44.44 | -39.69 | -35.21 | -37.40 |
| Return on Invested Capital % | 7.37 | -14.79 | -13.43 | -12.28 | -13.20 | -11.66 | -11.44 | -9.02 |
| Quick Ratio ratio | 5.94 | 8.32 | 9.28 | 9.16 | 9.79 | 10.27 | 9.56 | 8.46 |
| Current Ratio ratio | 6.21 | 8.37 | 9.28 | 9.16 | 9.79 | 10.27 | 9.56 | 8.46 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 70.13 | -127.55 | -128.45 | -128.55 | -126.90 | -124.12 | -132.97 | -114.75 |
| Depreciation | 6.32+114.2% | 3.57+17.4% | 2.85+22.3% | 6.50+251.4% | 2.95+60.3% | 3.04+56.7% | 2.33+7.9% | 1.85-15.1% |
| Other Funds (Non Cash) | -170.48-845.1% | 26.60+18.3% | 21.89+3.7% | 18.50-0.7% | 22.88+44.3% | 22.49+60.4% | 21.11+1053.6% | 18.63+45.7% |
| Funds from Operations | -94.03 | -97.38 | -103.71 | -103.55 | -101.08 | -98.58 | -109.53 | -94.27 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -23.41 | 0.38-98.4% | -27.50 | 5.02-52.4% | -6.22-120.5% | 23.29 | -21.93 | 10.55+80.3% |
| Cash from Operating Activities | -117.44 | -97.00 | -131.20 | -98.54 | -107.30 | -75.30 | -131.47 | -83.72 |
| Capital Expenditures | -8.21-694.9% | -29.61 | -2.47 | -1.52 | 1.38 | -4.28 | -5.08 | -5.09 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 194.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -169.60-400.4% | -74.47-145.9% | 96.93+306.8% | 22.29-87.4% | 56.45-42.1% | 162.21+56.9% | 23.83 | 177.30+135.5% |
| Purchase of Investments | -355.22 | -271.50 | -123.07 | -252.71 | -50.63 | 0.00 | -137.93 | -173.70 |
| Sale Or Maturity of Investments | 185.62+73.3% | 197.03+21.5% | 220.00+36.0% | 275.00-21.7% | 107.08-45.9% | 162.21-27.9% | 161.75-57.8% | 351.00-28.2% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 16.19-72.0% | -104.08-165.9% | 94.46+403.8% | 20.77-87.9% | 57.83-38.3% | 157.94+60.2% | 18.75 | 172.21+135.7% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 2.61+350.0% | 15.01+269.7% | 19.06+3130.5% | 192.15+4519.0% | 0.58-89.4% | 4.06-39.9% | 0.59-99.9% | 4.16-11.7% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 2.61+350.0% | 15.01+269.7% | 19.06+3130.5% | 192.15+4519.0% | 0.58-89.4% | 4.06-39.9% | 0.59-99.9% | 4.16-11.7% |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 12.37 | 188.93 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Issuance or Reduction of Debt, Net | -0.02 | -0.02 | -0.02 | -0.02 | -1.36 | -2.43 | -4.36 | -8.32 |
| Change in Long Term Debt | -0.02 | -0.02 | -0.02 | -0.02 | -1.36 | -2.43 | -4.36 | -8.32 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.02 | -0.02 | -0.02 | -0.02 | -1.36 | -2.43 | -4.36 | -8.32 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 200.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 2.59 | 14.98+824.7% | 219.04 | 192.13 | -0.78 | 1.62-76.0% | -3.76-100.8% | -4.17-188.5% |
| Net Change in Cash | -98.66 | -186.10-320.9% | 182.30 | 114.36+35.6% | -50.24-414.8% | 84.26+497.2% | -116.48 | 84.32 |
| Free Cash Flow | -118.45 | -97.81 | -133.67 | -100.06 | -105.92 | -79.58 | -136.55 | -88.81 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 9.79% | 14.7M | 150.1M | 1.57M |
| 2026-10-15 | 10.34% | 15.5M | 149.7M | 1.56M |
| 2026-09-30 | 10.33% | 15.5M | 149.7M | 1.55M |
| 2026-09-15 | 11.45% | 17.1M | 149.7M | 1.59M |
| 2026-08-31 | 11.12% | 16.6M | 149.7M | 1.65M |
| 2026-08-14 | 12.00% | 18.0M | 149.6M | 1.82M |
| 2026-07-31 | 11.64% | 17.4M | 149.8M | 1.88M |
| 2026-07-15 | 10.78% | 16.0M | 148.7M | 1.89M |
| 2026-06-30 | 10.72% | 15.9M | 148.7M | 1.81M |
| 2026-06-15 | 10.36% | 15.4M | 148.7M | 1.83M |
| 2026-05-29 | 10.08% | 15.0M | 148.8M | 1.77M |
| 2026-05-15 | 9.91% | 14.0M | 141.6M | 1.75M |
| 2026-04-30 | 10.46% | 14.8M | 141.7M | 1.70M |
| 2026-04-15 | 10.78% | 15.3M | 141.8M | 1.78M |
| 2026-03-31 | 10.90% | 15.4M | 141.5M | 1.80M |
| 2026-03-13 | 10.08% | 14.3M | 141.5M | 1.58M |
| 2026-02-27 | 10.12% | 14.3M | 141.5M | 1.69M |
| 2026-02-13 | 9.76% | 13.6M | 139.4M | 1.63M |
| 2026-01-30 | 9.69% | 13.6M | 139.9M | 1.63M |
| 2026-01-15 | 10.62% | 14.9M | 139.9M | 1.55M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 12.50 | 4.60 | 8.60 | 9.60 | 536.1% | 10.00 | 0.00 | 0.819 | -0.286 | 0.007 |
| call | 15.00 | 2.15 | 6.10 | 7.00 | 394.7% | 0.00 | 0.00 | 0.752 | -0.257 | 0.009 |
| call | 17.50 | 0.00 | 4.30 | 1.62 | 337.9% | 140 | 0.00 | 0.656 | -0.213 | 0.010 |
| call | 20.00 | 0.00 | 1.35 | 1.73 | 162.8% | 163 | 0.00 | 0.466 | -0.125 | 0.011 |
| call | 22.50 | 0.00 | 0.40 | 0.10 | 132.1% | 407 | 20.00 | 0.211 | -0.068 | 0.008 |
| call | 25.00 | 0.00 | 0.40 | 0.06 | 147.6% | 333 | 0.00 | 0.180 | -0.068 | 0.008 |
| call | 30.00 | 0.00 | 3.40 | 0.60 | 245.6% | 2.00 | 0.00 | 0.135 | -0.094 | 0.006 |
| put | 12.50 | 0.00 | 3.40 | 0.00 | 611.6% | 0.00 | 0.00 | -0.181 | -0.284 | 0.007 |
| put | 15.00 | 0.00 | 3.50 | 0.05 | 458.0% | 1.00 | 0.00 | -0.248 | -0.255 | 0.009 |
| put | 17.50 | 0.00 | 2.75 | 0.20 | 323.6% | 162 | 0.00 | -0.344 | -0.211 | 0.010 |
| put | 20.00 | 0.00 | 3.20 | 0.80 | 231.6% | 208 | 0.00 | -0.534 | -0.123 | 0.011 |
| put | 22.50 | 1.45 | 5.40 | 3.73 | 275.4% | 13.00 | 0.00 | -0.789 | -0.065 | 0.008 |
| put | 25.00 | 4.00 | 7.90 | 5.93 | 330.4% | 22.00 | 0.00 | -0.829 | -0.077 | 0.007 |
| put | 30.00 | 8.90 | 12.90 | 0.00 | 414.9% | 0.00 | 0.00 | -0.865 | -0.091 | 0.006 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-03 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-03 | 8-K | Current report | 2026-11-03 | SEC |
| 2026-09-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-02 | SEC |
| 2026-09-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-01 | SEC |
| 2026-09-02 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-01 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-11 | SEC |
| 2026-08-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-08-04 | SCHEDULE 13G/A | SEC | ||
| 2026-07-28 | 8-K | Current report | 2026-07-27 | SEC |
| 2026-07-08 | SCHEDULE 13G/A | SEC | ||
| 2026-06-18 | 8-K | Current report | 2026-06-12 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-04 | 8-K | Current report | 2026-06-03 | SEC |
| 2026-05-22 | 8-K | Current report | 2026-05-21 | SEC |
| 2026-05-15 | SCHEDULE 13G | SEC | ||
| 2026-05-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-07 | 8-K | Current report | 2026-05-07 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 363.68K | 3 |
| 2026-08 | 0 | 0 | 71.62K | 1 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 864.86K | 2 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| T. Rowe Price Investment Management, Inc. | 10.19% |
| BlackRock, Inc. | 8.84% |
| BAILLIE GIFFORD & CO | 6.96% |
| Temasek Holdings | 4.39% |
| STATE STREET CORP | 4.18% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.08% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.95% |
| FMR LLC | 2.84% |
| GOLDMAN SACHS GROUP INC | 2.62% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.53% |
Funds
| Fund | % owned |
|---|---|
| T. Rowe Price Capital Appreciation Fund | 3.13% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.70% |
| iShares Russell 2000 ETF | 2.40% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.19% |
| VANGUARD SMALL-CAP INDEX FUND | 1.95% |
| VANGUARD U.S. GROWTH FUND | 1.68% |
| SMALLCAP World Fund Inc | 1.57% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.47% |
| VANGUARD SMALL-CAP GROWTH INDEX FUND | 1.12% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.09% |
OakChart. DNLI. Cached 15 minutes. Terms